학술논문
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)
Document Type
Erratum
Author
Bello Roufai, D.; Cottu, P.; Pierga, J.Y.; Loirat, D.; Renouf, B.; Bidard, F.C.; Lerebours, F.; Gonçalves, A.; Bertucci, A.; De La Motte Rouge, T.; Robert, L.; Akla, S.; Delaloge, S.; Blonz, C.; Bertho, M.; Grenier, J.; Gligorov, J.; Benderra, M.-A.; Saghatchian, M.; Bailleux, C.; Simon, H.; Renaud, E.; Desmoulins, I.; Tharin, Z.
Source
In: Oncogene . (Oncogene, 21 April 2023, 42(17):1417)
Subject
Language
English
ISSN
14765594
09509232
09509232